Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044

Core Insights - Adial Pharmaceuticals has filed a new patent application for its lead investigational drug AD04, aimed at treating Alcohol Use Disorder (AUD) in heavy drinking patients, with expected protection extending to at least 2044 [1][2] - The company is advancing the AD04 program alongside a pharmacokinetics study, and the new patent application is a result of a thorough examination of data after hiring new patent counsel [2] - AD04 is a genetically targeted, serotonin-3 receptor antagonist that has shown promising results in reducing drinking in heavy drinking patients during the ONWARD™ pivotal Phase 3 clinical trial, with no significant safety or tolerability concerns [3] Company Overview - Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for addiction and related disorders, with AD04 being its lead investigational new drug [3] - The company believes AD04 may also have potential applications in treating other addictive disorders such as Opioid Use Disorder, gambling, and obesity [3]